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Abstract
Background: Hemophilia A represents the most common and severe inherited hemorrhagic
disorder. It is caused by mutations in the F8 gene, which leads to a deficiency or dysfunctional factor
VIII protein, an essential cofactor in the factor X activation complex.
Methods: We used long-distance polymerase chain reaction and denaturing high performance
liquid chromatography for mutation scanning of the F8 gene. We designed the competitive
multiplex PCR to identify the carrier with exonal deletions. In order to facilitate throughput and
minimize the cost of mutation scanning, we also evaluated a new mutation scanning technique, high
resolution melting analysis (HRM), as an alternative screening method.
Results: We presented the results of detailed screening of 122 Taiwanese families with hemophilia
A and reported twenty-nine novel mutations. There was one family identified with whole exons
deletion, and the carriers were successfully recognized by multiplex PCR. By HRM, the different
melting curve patterns were easily identified in 25 out of 28 cases (89%) and 15 out of 15 (100%)
carriers. The sensitivity was 93 % (40/43). The overall mutation detection rate of hemophilia A was
100% in this study.
Conclusion: We proposed a diagnostic strategy for hemophilia A genetic diagnosis. We consider
HRM as a powerful screening tool that would provide us with a more cost-effective protocol for
hemophilia A mutation identification.
Background
Hemophilia represents the most common and severe
inherited hemorrhagic disorder. Hemophilia A(HA) is
caused by mutations in the F8 gene, leading to a defi-
ciency or dysfunctional III protein, an essential cofactor in
the factor X activation complex. The F8 gene is 186 kb
long; it has 26 exons and encodes a 9-kb mRNA transcript
[1,2]. The mutations causing hemophilia A are spread
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throughout the gene and are mostly represented by point
alterations. However, the inversion of intron 22 was
found in 40–50% of patients with severe HA [3] and the
inversion of intron 1 was reported with a prevalence of
about 5% in the UK [4].
Patients suffering from the disorder, along with their fam-
ilies, bear great financial and social burden; therefore, it is
very important to prevent recurrence of the disease. For
the sake of genetic counselling and prenatal diagnosis of
hemophilia A, it is necessary to establish a sensitive, rapid
and economic genetic diagnostic system. However, com-
prehensive analysis of mutations in the F8 gene is difficult
to conduct due to the large gene size, its many scattered
exons, and the high frequency of de novo mutation. The
most direct strategy for mutation detection would be to
amplify these regions from genomic DNA using PCR [5].
However, it would necessitate almost 30 amplifications of
genomic DNA to cover all the essential regions.
The first systematic analysis of the complete coding
sequence of the F8 gene was performed by applying dena-
turing gradient gel electrophoresis (DGGE) after PCR
amplification in 1991. The analysis demonstrated a 90%
mutation detection rate [6]. Since then, a wide range of
different mutations have been identified, providing the
genetic basis for the extensive variability observed in the
clinical phenotypes. Mutation detection in the F8 gene is
so challenging that it is only partially met by conventional
screening methods such as single stranded conforma-
tional polymorphism (SSCP), conformational sensitive
gel electrophoresis (CSGE) and chemical mismatch cleav-
age (CMC), each with varying applicability and efficiency;
however, they all suffer from incomplete detection rates in
the range of 70–85% [7-11]. Moreover, each method
places variable demands on the technical skills and time
investment of the investigator. In contrast, the recently
introduced denaturing high performance liquid chroma-
tography (DHPLC) offers a promising new method for a
fast and sensitive analysis(96.2%) of PCR-amplified DNA
segment [12-15].
We have established a diagnostic strategy, consisting of
screening for most common mutations in the F8 gene,
using long-distance polymerase chain reaction (LD-PCR)
and DHPLC. We reported the result of detailed screening
of 122 Taiwan families with hemophilia A. In order to
facilitate throughput and minimize the cost of mutation
scanning, we also evaluated a new mutation scanning
technique, high resolution melting analysis (HRM). This
alternative screening technique detects sequence variation
by the use of a saturating double-stranded DNA dye.
Methods
Patients
This study was approved by the Ethic Institute Review
Board of National Taiwan University Hospital and
included 122 families, in which 329 samples had hemo-
philia A family history. We obtained consent from each
subject. The patients presented varying degrees of severity
of the disease. The mild and moderate hemophilia A was
diagnosed following the familial transmission analysis
and after the elimination of von Willebrand disease type
2N either by FVIII:vWF binding test or sequencing of exon
18 to 24 of the von Willebrand gene.
DNA extraction
According to the manufacturer's instructions, genomic
DNA was extracted from 3 ml of peripheral blood cell
samples with a Puregene DNA Isolation Kit (Gentra Sys-
tems, Minneapolis, MN).
DNA mutation numbering is based on cDNA sequence
and nucleotide +1 corresponds to A of the ATG translation
initiation codon. The nomenclature of this study follows
the Nomenclature for Description of Genetic Variations
approved by the Human Genome Variation Society and
differs in 19 amino acids from the reference mutation
database because the first 19 amino acids compose a sig-
nal peptide.
Mutation identification
The PCR assay for intron 22 inversion
The PCR mixture contained a total volume of 50 μl: 1 mM
10× buffer, 76 mM DMSO, 0.5 mM of dNTP and 0.3 mM
deaza-Dgtp(Amershan Biosciences; Freiburg Germany),
0.12 mM of Expand long Template DNA polymerase
(Roches) and 0.36 mM each of primer P, Q, 0.06 mM each
of primer A, B as described by Qiang Liu et al. [16,17].
Subcycling multiplex long distance PCR(LD-PCR) was
carried out as described by Qiang Liu et al. [16,17] with
slight modifications in the reaction temperatures. The
conditions for LD-PCR for the first 10 cycles were set at
94°C for 12s, followed by four subcycles of annealing/
elongation carried out at 62°C for 120s and 65°C for
120s. The remaining 20 cycles were modified by the addi-
tion of an extra 5s per cycle for each of the annealing/elon-
gation step. 10 μl of PCR product were mixed with TAE
buffer and electrophoresed for one hour on a 0.7% agar-
ose gel, then stained with ethidium bromide and visual-
ized under UV Light.
The PCR assay for intron 1 inversion
The PCR amplification of the F8 intron 1 region and the
intron 1 h repeats were performed on 100 ng of genomic
DNA, in a reaction volume of 25 μl containing 0.1 mM
dNTP, 2 mM MgCl2, 10 mM buffer and 0.5 units TaqBMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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polymerase (Perkin Elmer, ABI Foster City, CA). The prim-
ers used for the amplification of the F8 intron 1 region
were 0.12 mm of 9F, 9CR and int1h-2F each. Primers
int1h-2F, int1h-2R and 9F were used for the amplification
of intron 1 h repeats as previously described by Tizzano
and Banagnall et al. [18,19]. After the initial denaturing
step at 95°C for 5 min, thirty cycles of PCR were carried
out designated at 94°C for 30s, 65°C for 30s and 72°C for
2 min. Finally, 5 μl of PCR products were mixed with TAE
buffer and electrophoresed for one hour on a 0.7% agar-
ose gel, then stained with ethidium bromide and visual-
ized under UV light.
PCR assay and DHPLC for entire coding region
If there was no inversion in intron 1 or intron 22, we per-
form mutation analysis of the entire F8 coding region,
including flanking splicing sites, by DHPLC using appro-
priate primers (Table 1). The DHPLC allows for the auto-
mated detection of single base DNA substitutions as well
as small insertions and deletions. When using heterodu-
plex analysis by DHPLC under partially-denaturing condi-
tions, heteroduplexes are retained less than their
corresponding homoduplexes on a unique DNA separa-
tion matrix. DHPLC uses unpurified PCR products that
are subjected to a final denaturing/reannealing step to
ensure adequate formation of the heteroduplex. The
cycling parameters of the amplification reactions were
optimized for the fragment. Equal volumes of the
polymerase chain reaction (PCR) product from the
patient and from a wild-type control male were mixed,
denatured at 95°C for 5 min and then incubated at 65°C
for 30 min to obtain heteroduplexes. Mutational screen-
ing, performed on all amplified fragments from each
patient, was carried out via denaturing high-performance
liquid chromatography (DHPLC) on a Wave® DNA Frag-
ment Analysis System (Transgenomic Inc., San Jose, CA)
with a DNASep column (Transgenomic). The DNASep
column contains proprietary 2-mm nonporous alkylated
poly (styrene divinylbenzene) particles. The DNA mole-
cules eluted from the column are detected by scanning
with a UV detector at 260 nm. DHPLC-grade acetonitrile
(9017-03; J.T. Baker, Phillipsburg, NJ) and triethylammo-
nium acetate (TEAA; Transgenomic, Crewe, UK) consti-
tuted the mobile phase [14,20]. For DHPLC analysis,
heterozygous profiles were identified by visual inspection
of the chromatograms.
Samples showing an abnormal peak pattern were
sequenced using a fluorescent ABI Prism BigDye termina-
tor kit (Applied Biosystems, UK), and the mutations were
characterized. Each mutation was confirmed on a second,
independent, amplified PCR sample. In order to rule out
the possibility of exonic polymorphisms, 150 DNA sam-
ples from healthy, unrelated controls were screened and
found negative for the novel missense mutations. All
mutations found in the patients' family members were
confirmed by sequencing.
High Resolution Melting Analysis
Melting curve analysis with the high-resolution melting
instrument is a simple, high-performance, reliable, high-
resolution, time-saving, and low labor-intensive tech-
nique that has shown promise as a sensitive and specific
tool for the detection of variations in DNA. The thermal
stability of a PCR product is determined by its base
sequence [21,22]. When the PCR product sequence is
altered, duplex stability is changed, leading to different
melting behavior. During high resolution melting analy-
sis, melting curves are produced using dyes that fluoresce
in the presence of double-stranded DNA and specialized
instruments designed to monitor fluorescence during
heating; as the temperature increases, the fluorescence
decreases, producing a characteristic melting profile. The
melting curve data were normalized, temperature-shifted,
and converted to melting peaks by plotting the negative
derivative of the fluorescence with respect to temperature
against temperature (-dF/dT vs. temperature). This melt-
ing data can be analyzed to detect sequence variations
such as single nucleotide polymorphisms and small inser-
tions and deletions.
PCR amplification mixture included 2.5 mM MgCl2, 5 μl
2× Master Mix, 3.1 μl H2O (from Roche Reaction Mix Kit,
Mannheim, Germany), 0.2 mM primers. And we added
25 ng DNA template. PCR amplification began with the
first denaturation step at 95°C for 10 min, followed by 25
cycles of denaturation at 94°C for 30 s, annealing at 53°C
for 45 s, extension at 72°C for 45 s, and then a final exten-
sion step at 72°C for 10 min.
Pipet 10 μl PCR products into each well of the LightCy-
cler® 480 (Roche Applied Science) Multiwell Plate. Seal
Multiwell Plate with LightCycler® 480 Sealing Foil. Load
the multiwall Plate in LightCycler® 480 instrument and
start the melting program. High resolution melting was
performed at 95°C for 1 min, 40°C for 1 min, 6.5°C for
1 s and acquisitions at 95°C. The data was evaluated using
the LightCycler® 480 Gene Scanning Software.
In order to improve the melting analysis, we redesigned
the primers for some exons to shorten the PCR product
and to avoid DNA-dimer formation (Table 2).
Multiplex PCR by Capillary Electrophoresis
In one family, the band of exon 4 to exon 10 by electro-
phoresis after PCR was visible in female cases but not in
affected male patients. Large deletion was suspected, so
we designed multiplex PCR in order to differentiate nor-
mal female from female carriers.BMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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Table 1: Primer pairs and PCR conditions for DHPLC analysis.
HA Primer pairs and PCR conditions for DHPLC analysis




DHPLC oven (°C) Elution profile(B%)
1F ACATCCAGTGGGTAAAGTTC 356 53 60 55 56–65 52–61
1R AGACTTACATCCCCACAATC
2F TTGAAGTGTCCACCAAAATGAACGACT 211 54 59 48–57
2R GATACCCAATTTCATAAATAGCATTCA
3F GTACTATCCCCAAGTAACCTT 204 54 59 50–59
3R CATAGAATGACAGGACAATAGG
4F TACAGTGGATATAGAAAGGAC 296 54 57 54–63
4R TGCTTATTTCATCTCAATCCTACGCTT
5F CCTCCTAGTGACAATTTCCTA 188 54 55 49–58
5R AGCAGAGGATTTCTTTCAGGAATCCAA
6F CATGAGACACCATGCTTAGCT 224 54 60 51–60
6R AACTCTGGTGCTGAATTTGGAAGACCCT
7F CAGATTCTCTACTTCATAGCCATAG 324 54 58 56 55–64 53–62
7R ATTAAAAGTAGGACTGGATA
8F ATATAGCAAGACACTCTGACA 338 54 58 55–64
8R AGAGAGTACCAATAGTCAAA
9F AGAGTTGGATTTGAGCCTACC 284 54 58 55 53–62 50–59
9R CAGACTTTTTCTTCTTACCTGACCTT
10F GGATTTGATCTTAGATCTCGC 204 53 56 54 50–59 48–57
10R ATTTTAGTTGTTATTGATGA
11F TTGAGCTATTTATGGTTTTG 294 53 58.5 56 53–62 51–60
11R GACATACACTGAGAATGAA
12F GCATTTCTTTACCCCTTTCA 230 54 59.5 57 51–60 49–58
12R CTTTATTCACCACCCACTG
13F TCCTGGGAATAAGATAATGG 393 54 57.5 56 56–65 54–63
13R AGAGCATACGAATGGCTAGT
14(I)F ATCTGTGTTATGAGTAACCA 430 54 57.5 57–66
14(I)R TCATATTTGGCTTCTTGGAG
14(II)F CATGGGCTATCCTTATCTGA 479 54 56.5 57–66
14(II)R CATGAACTTTCTTGGCTATT
14(III)F TCAAAGTTGTTAGAATCAGG 441 54 55.5 56–65
14(III)R ATTTTGTGCATCTGGTGGAA
14(IV)F GTCCAACAGAAAAAAGAGGG 481 54 57 54.5 58–67 55–64
14(IV)R CTACATTTTGCCTAGTGCTC
14(V)F CTGGCACTAAGAATTTCATG 429 54 57.5 56 57–66 55–64
14(V)R CCTTCTCATTGTAGTCTATC
14(VI)F GAAACATTTGACCCCGAGCA 431 54 57.5 56–65
14(VI)R TTTTGGGCAAGTCTGGTTTC
14(VII)F CACATACAAGAAAGTTGAGA 436 54 59 57.5 56–65 55–64
14(VII)R CTCATTTATTGCTGCTATTG
14(VIII)F GATACCATTTTGTCCCTGAA 415 54 57.5 56–65
14(VIII)R GTCACAAGAGCAGAGCAAAG
15F CACCTAGGAAAATGAGGATGT 300 53 58.5 56 53–62 51–60
15R ATAGTCAGCAAGAAAATAAA
16F AAGATCCTAGAAGATTATTC 330 50 57.5 53–62
16R TTAGTACACAAAGACCATTT
17F TGATGAGAAATCCACTCTGG 349 54 58 56.5 54–63 53–62
17R GTGCAATCTGCATTTCACAG
18F GTGGAATCCTCATAGATGTCA 312 53 57 54–63
18R GAGTAGGTAGAAGAAAGAGCAC
19F GCAAGCACTTTGCATTTGAG 305 52 59 56 55–64 52–61
19R AGCAACCATTCCAGAAAGGA
20F CCATTTTCATTGACTTACATTTGAG 193 53 59.5 56.5 49–58 46–55
20R AGATATAATCAGCCCAGGTTC
21F GAATTTAATCTCTGATTTCTCTAC 168 53 60.5 56 48–57 46–55
21R GAGTGAATGTGAATACATTTCCBMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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Multiplex PCRs were used to optimize the system and
allowed the amplification of exon 3 to exon11. The KRIT
and FGFR2 genes were used as internal controls. Each
multiplex PCR for the DNA fragments was performed in a
total volume of 25 μL containing the following: 100 ng of
genomic DNA; 0.1 to 0.5 μM each primer; 200 μM dNTPs;
1 unit of AmpliTaq Gold enzyme (PE Applied Biosys-
tems); and 2.5 μL of GeneAmp 10× buffer II (10 mmol/L
Tris-HCl, pH 8.3, 50 mmol/L KCl) in 2 mM MgCl2 as pro-
vided by the manufacturer. PCR amplification was carried
out with an initial denaturation step at 95°C for 10 min,
followed by 25 cycles of denaturation at 94°C for 30 s,
annealing at 53°C for 45 s, extension at 72°C for 45 s, and
then a final extension step at 72°C for 10 min.
The HDA system with GCK-5000 cartridge kit (eGene)
was used to analyze exons of the F8 gene. The gel-matrix
in the gel cartridge consists of proprietary linear polymer
with ethidiumbromide (EtBr) dye. The PCR products were
diluted 20-fold by deionized water and placed in the sam-
ple chamber of the instrument. The DNA samples were
then automatically injected into the capillary channel and
subjected to electrophoresis according to the manufac-
turer's operation protocol. BioCalculator Graphing soft-
ware (eGene) enabled automatic labelling of the peak
sizes.
Results
Genomic DNA from 122 HA unrelated families were ana-
lyzed for mutations in the F8 gene (Table 3). There were
128 affected patients identified. This resulted in the iden-
tification of 61 different F8 gene mutations. The mutation
detection rate was 100%.
Screening of the F8 intron inversion
There were fifty-three (42.7%) families with intron 22
inversion (Fig. 1a) and one (0.8%) family with intron 1
inversion (Fig. 1b &1c) in this study. Since the intron 1
and the intron 22 inversion were well established causa-
tive mutations [3], there would be no need to search for
other mutations in the coding regions in these families.
Screening of the F8 mutation by DHPLC and direct 
sequencing
We performed DHPLC for mutation screening in those
families who didn't have intron 1 and intron 22 inver-
sions. By DHPLC, 100% genetic mutation was detected in
the 119 HA families and confirmed by sequencing. The
two X chromosomes from the carriers are responsible for
the heteroduplex formation of the PCR amplicons. These
stutter peaks (heteroduplex) were eluted much earlier in
the chromatographic process than the main peaks
Result of inversion detection of intron 1 and intron 22 Figure 1
Result of inversion detection of intron 1 and intron 
22. a) LD-PCR result of intron 22 inversion. Wild type has 
two band with PQ segment (12 KB) and AB segment (10 
KB). With intron 22 rearrangement, PQ segment will be 
interrupted so that PB and AQ (both 11 KB) form. That is 
why we can see all three bands in carrier. Patient will show 
only 11 KB and 10 KB bands. Patient 154 is proved to be an 
affected case. M, marker. C, carrier. P, known affected male 
patient. WT, wild type. b) PCR result of intron 1 inversion. 
Set 1 is the product of primer 9F, int-2F and 9CR. In wild 
type, the only segment amplified is 1908 bp. In the affected 
male patient with intron 1 inversion, the amplified segment is 
1323 bp in length. c) Set 2 is the product of primer 9F, int-2F 
and 2R. 93-2, 104-1 and 104-2 are normal. 93-1 is proved to 
be an affected case. 93-3 is a carrier with heterogenous com-
ponents.
22F AAATAGGTTAAAATAAAGTGTTAT 206 53 48 48–57
22R GACTAATTACATACCATTAAG
23F CTCTGTATTCACTTTCCATG 250 54 57 52–61
23R ACAGTTAGTCACCCTACCCA
24F GCTCAGTATAACTGAGGCTG 249 54 58.5 51–60
24R CTCTGAGTCAGTTAAACAGT
25F AGTGCTGTGGTATGGTTAAG 323 56 58 56.5 55–64 54–63
25R TTGCTCTGAAAATTTGGTCATA
26F ATCCTGGACTACTGGAAACA 393 53 63 58.5 56–65 51–60
26R AGTTAATTCAGGAGGCTTCA
Table 1: Primer pairs and PCR conditions for DHPLC analysis. (Continued)BMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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(homoduplex). Yet, the affected male patients with one X
chromosome would not form a heteroduplex until it is
mixed together with the wild type DNA (Fig. 2).
Evaluating of High-Resolution Melting Analysis
In order to evaluate the HRM analysis, 25 families, includ-
ing a total of 43 samples with known mutation and 341
normal controls were tested. The mutations consisted of
13 different missense mutations, 5 deletions, 4 insertions,
2 nonsense mutations, one splicing site nucleotide substi-
tution and one duplication.
In order to avoid DNA-dimer formation, we redesigned
the primers for the HRM PCR reaction. The resulting melt-
ing curves were easier to differentiate from normal con-
trols and the sensitivity was elevated. Figure 3 compares
the melting curves of the original and modified primers,
respectively. As temperature increased, the double strand
DNA was unwound and the fluorescence was released (Fig
3a and 3b). The melting curves were normalized by calcu-
lation of the "line of best fit" in between two normaliza-
tion regions before and after the major fluorescence
decrease representing the melting of the PCR product
using the software the LightCycler® Gene Scanning Soft-
ware 4.0. The samples with high signal difference would
present different peaks from the wild type (Fig 3d).
The different melting curve patterns were easily identified
in 25 out of 28 cases (89%) and 15 out of 15 (100%) car-
riers. The sensitivity of HRM in this study was 93 % (40/
43).
In addition, we performed HRM for whole coding region
scanning in three families with unknown mutations.
Three abnormal melting curves were identified. After
these exons were confirmed by direct sequencing, we were
able to identify the mutation in these three families. The
specificity of HRM in this pilot study was high but it
required further investigation. A larger sample sizes was
needed for validation.
Multiplex PCR
There were two families, which we were unable to see the
exon 4 to exon 10 band and the Exon1 band from electro-
phoresis after PCR, respectively. For the former, we
designed the multiplex PCR that showed a total deletion
from exon 4 to exon 10 (Fig 4). The ratio of the defective
exon to the control gene in peak heights (the exon 4 to
exon 10/the KRIT and the exon 4 to exon 10/the FGFR2)
in the female carrier was half of that of the wild type. That
is, the relative gene dosage in exon 4 to the exon 10 of the
wild type was two times to that of the female carrier. As for
the other family, we were unable to perform the multiplex
PCR without having the DNA of the obligate carrier.
In this study we identified twenty-eight missense muta-
tions, thirteen nonsense mutations, one four- base pair
duplication, five insertions, nine small deletions, one
splicing site nucleotide substitution and two large seg-
ment deletions in the F8 gene.
We identified twenty-nine novel mutations of the F8 gene
in hemophilia A patients, in which eleven were missense
mutations, one was splicing site substitution, seven were
nonsense mutation, which lead to premature terminating
of the protein, and ten were frameshift mutations includ-
ing one four-base pair duplication, four deletions and five
insertions, resulting in truncations of the F8 protein.
None of the novel missense mutations were presented in
the 150 normal DNA samples.
Discussion
The most common mutation, found in approximately
40% of patients with severe hemophilia A, was the intron
22 inversion mutation [23]. This mutation happens when
homologous recombination occurs between the Int22h-1
in intron 22 and 1 of 2 homologous regions (Int22h-2 or
Int22h-3) telomeric to the F8 gene. An additional inver-
sion of intron 1 of the factor VIII gene that affects up to
Result of DHPLC Figure 2
Result of DHPLC. DHPLC results of two families were 
illustrated. a) Family 85. b) Family 139. The wild type DNA 
showed homoduplex. The carrier DNA would show heter-
oduplex peak just as affected male after mixing with normal 
DNA.BMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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Table 2: Redesigned primer pairs for HRM
Exon Oligo (5' – 3') product size
HA – 1-1F CCACTGATAAAAAGGAAGCA 226
HA – 1-1R GTGGAGAGCTCTATTTGCAT
HA – 1-2F CCTCCTGGGAGCTAAAGATA 248
HA – 1-2R CGATCAGACCCTACAGGA
HA – 4-1F CTTTGAGTGTACAGTGGATATAGAA 200
HA – 4-1R AAAGATATGAGTAGGTAAGGCACA
HA – 4-2F TGATAAAGTCTTCCCTGGTG 209
HA – 4-2R TGCTTATTTCATCTCAATCCT
HA – 7-1F CCTAGCAAGTGTTTTCCATT 246
HA – 7-1R AGGTCCATCAAGAGTGTTTG
HA – 7-2F GCCACAGGAAATCAGTCTAT 236
HA – 7-2R TTCATTTTAAAGATCCAAGA
HA – 8-1F TGAGCCAATTCAATCTCTTT 237
HA – 8-1R ATCATCAAACCTGACCACAT
HA – 8-2F TAATGAAGAAGCGGAAGACT 245
HA – 8-2R TTTTGAGTATGGGGAAGAGA
HA – 9F CCCAACCTCTCATCTTTTT 250
HA – 9R CCAGACTTTTTCTTCTTACCTG
HA – 11-1F CAGATTTGTAGAACCCTTGC 216
HA – 11-1R TAGAGTAATAGCGGGTCAGG
HA – 11-2F CTGCCAGGAGAAATATTCAA 239
HA – 11-2R AAGGGGACATACACTGAGAA
HA – 13-1F CATGACAATCACAATCCAAA 244
HA – 13-1R AGAATGGGAATAGGGTGAGT
HA – 13-2F GAGGTGGCATACTGGTACAT 219
HA – 13-2R ATACGAATGGCTAGTGAAGC
HA – 14-1F CTGTGTTATGAGTAACCAGAGT 243
HA – 14-1R CCTAGTGCTAGGGTGTCTTG
HA – 14-2F AATGCCATTGAACCAAGA 238
HA – 14-2R CATATTTGGCTTCTTGGAGA
HA – 14-3F TCTTGCGACAGAGTCCTACT 242
HA – 14-3R TTTCTTCAACTCTGTTGCTG
HA – 14-4F TCAGGCCTCCAATTAAGAT 250
HA – 14-4R GGTCCACCAGACTCAGTAAG
HA – 14-5F AGA TAC CAC TCT ATT TGG CA 229
HA – 14-5R AAC TTT GAA TAA GGC ATT A
HA – 14-6F TGGTAGGTTATTTAAAGGGAAA 248
HA – 14-6R GCATTCTGTCATGAATCAAA
HA – 14-7F CCATCAGTCTGGCAAAATA 250
HA – 14-7R ATCCACCTTGCTGATTCTG
HA – 14-8F CACAAAATCCAGATATGTCGT 235
HA – 14-8R CCATCTCTTTGAGTCCTACG
HA – 14-9F AGGAAAGGGTGAATTTACAA 249
HA – 14-9R TTTTGCCTAGTGCTCAGTAA
HA – 14-10F TTGCCTCAGATACATACAGTG 250
HA – 14-10R TGCATGCATATTTCTCTACAA
HA – 14-11F AAAACTTGGAAGGCTTGG 250
HA – 14-11R TTGTAGTCTATCTGTGTGAGG
HA – 14-12F GGTCCAAAAACATGAAACAT 245
HA – 14-12R ATAAGATGCTGCTGGAAGAT
HA – 14-13F GGTCCTATTCCAAGACAACTC 250
HA – 14-13R AGATGTTTTGGGCAAGTCT
HA – 14-14F CACATACAAGAAAGTTGAGAACA 250
HA – 14-14R GCTTTCTGTTGCTACTCTCAG
HA – 14-15F TGGAATGAAGCAAACAGAC 250
HA – 14-15R TTTGTCCCTCATTTATTGCT
HA – 14-16F ATACCATTTTGTCCCTGAAC 249
HA – 14-16R TGTCAAAATCTTCCTTCTTCA
HA – 14-17F TTCAGTCAGATCAAGAGGAAA 246BMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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5% of patients with severe hemophilia A has been
reported [18]. The large size of the F8 gene predisposes to
the occurrence of deletions, which account for approxi-
mately 5% of characterized mutations. Single base pair
changes (resulting in missense, frameshift, or splice junc-
tion mutations), insertions, or duplications account for
the balance of cases of hemophilia A that are spread
throughout the F8 gene [24]. Although the structure-func-
tion relationships of some of the missense mutations are
known or can be deduced (eg, alteration of vWF binding
site, thrombin cleavage site, etc), the structural conse-
quences of most such mutations remain undefined [25].
Our data showed a mutation detection rate at 100% out
of 122 hemophilia A families. Since the intron 22 inver-
sion and intron 1 inversion present in 45.1 % in this Tai-
wanese database, 47.5 to 53% in India population [8,26]
and 40–50% in European [3,18], it is rational to perform
the inversion detection of intron 1 and intron 22 at first,
and then genetic scan if no intron 1 or 22 inversion were
found. In our cohort, 54.5% severe HA families had
intron 1 and intron 22 inversion; 65.5% cases with intron
1 and intron 22 inversion belonged to severe hemophilia
A patients. It is also suggested to check for intron 1, intron
22 inversion and big deletions in cases having the severe
phenotype; on the other hand, it is recommended to go
directly to the F8 gene mutation scanning in cases having
the moderate/mild phenotype [25,27]. However, we are a
referred center and the clinical data is not always availa-
ble. Because the inversion detection of intron 1 and intron
22 is cheaper and more time-saving than other tech-
niques, our strategy seemed to be economical under this
situation.
The B domain accounts for 40% of the F8 cDNA. Apart
from large exon or intron deletions, fourteen (14/52,
26.9%) different mutations and one SNP were found to
be located in the B domain of the F8 cDNA. All mutations
belonging to deletion, insertion, or nonsense mutations,
lead to different protein products. This may imply the low
functional importance of this region since no phenotype
would be identified unless the protein product is changed
or truncated. The SNP identified in the B domain was
located in c. 3780 on exon 14, which changed aspartic
acid to glutamic acid. Through family studies in a Cauca-
sian population, Machiah et al. hypothesized that
Asp1241Glu influences about 5% F8 levels and modifies
thrombosis risk by modulating the rate of secretion into
the circulation by family studies [28]. Scanavini et al. also
conducted a case-control study and demonstrated that the
F8 D1241E polymorphism was associated with decreased
F8 activity [29].
Affected males with large deletions can be readily detected
by the absence of an amplification product in PCR. Up to
98% of all frequent deletions can be detected, but in car-
riers, the nondeleted X chromosome hampers detection,
making identification of hemophilia A carrier status diffi-
cult. In one particular family, the PCR product of an
affected male patient failed to show exon 4 to exon 10. But
of the same family, the same exon region in the female
cases was successfully amplified by PCR and sequenced.
Large deletion was suspected, but we were unable to dis-
HA – 14-17R TCAAATGTCACAAGAGCAGA
HA – 15F TATTGCTTTTCCTCTGCTTT 214
HA – 15R TTTCTTGTAATTCCACTGTCC
HA – 16-1F GGGATGTAAACCCTAAGGAC 228
HA – 16-1R ATGATGTTGCACTTTCCAA
HA – 16-2F CTCTCGTCCCTATTCCTTCT 232
HA – 16-2R TAAACCAAAAAGTGGTCAGC
HA – 17-1F ACTCATAGGATTGATGTCTTCC 238
HA – 17-1R TAAAAGTGGGATCTTCCATC
HA – 17-2F CTAACACACTGAACCCTGCT 241
HA – 17-2R TCATTTGTCAAAGTGCAATC
HA – 18F TTTTAACAGGCTTCTCTGTG 246
HA – 18R AGGTAGAAGAAAGAGCACAAAC
HA – 19F AAATAATTTCTGTTCCTGTTG 222
HA – 19R ATTCCAGAAAGGAAGAAAGC
HA – 25-1F GGT GAC CAA GAG GCT AC 170
HA – 25-1R GAC TGC TGG AGA TGA GGA
HA – 25-2F CAG GGA GTA AAA TCT CTG C 155
HA – 25-2R TGG TAT TTT TTT TCT TTC TT
HA – 26-1F AGAAGTGAGAAAAGCGTCTG 244
HA – 26-1R ACCCTCAGTAGAGGTCCTG
HA – 26-2F GAATTCACCCCCAGAGTT 234
HA – 26-2R AGAAATGCAGGACTGATGAT
Some of the primers used for HRM were redesigned by LightCycler Probe Design Software 2.0. The primers not listed were the same with table 1
Table 2: Redesigned primer pairs for HRM (Continued)BMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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Table 3: The detailed patient data.
Case number Gender Diagnosis Result Reported/Novel HRM result FVIII:C Severity
69-1 M Affected case Exon 1 deletion R <1% severe
61-1 M Affected case Exon 2, c.185, C>G, TCA>TGA, Ser>X N <1% severe
109 M Affected case Exon 3, c.278, C>T, CCT>CTT, Pro>Leu N V <1% severe
82 M Affected case Exon 3, c.278, C>T, CCT>CTT, Pro>Leu N <1% severe
144 M Affected case Exon 3, c.336_339, dup CCAT N indistinguishable 1.6% moderate
71-1 F Carrier Intron 3, c.289-9 C>T N V
42-3 M Affected case Exon 4, c.403 G>A, GAT>AAT, Asp>Asn N <1% severe
59-1 M Affected case Exon 4, c.532, C>G, CTT>GTT, Leu>Val N <1% severe
118-1 M Affected case Exon 4~Exon 10 deletion R 1.1% moderate
122 M Affected case Exon 7, c.829, A>G, ATT>GTT, Asp>Gly N V 12% muld
114 M Affected case Exon 7, c.854_855, ins G N V 2.4% moderate
79-1 M Affected case Exon 7, c.977 T>C, CTA>CCA, Leu>Pro R <1% severe
94-1 M Affected case Exon 7, c.977 T>C, CTA>CCA, Leu>Pro R <1% severe
16-3 M Affected case Exon 8, c.1247, C>T, CCC>CTC, Pro>Leu N 4.2% moderate
101 F Carrier Exon 9, c.1310 G>C, CGG>CCG, Arg>Pro R V
72-1 M Affected case Exon 9, c.1315 G>A, GGT>AGT, Gly>Ser R 3.0% moderate
162 M Affected Exon 9, c.1336, C>T, CGA>TGA, Arg>X R 4.8% moderate
110 M Affected case Exon 9, c.1400, T>G, ATC>AGC, Ile>Ser N V 0.6% severe
65 M Affected case Exon 11, c.1636, C>T, CGG>TGG, Arg>Trp R 2.3% moderate
92 M Affected case Exon 11, c.1648, C>T, CGC>TGC, Arg>Cys R 12.0% mild
136 M Affected case Exon 11, c.1678, A>G, AGA>GAA, Arg>Gly N V 11.0% moderate
98 M Affected case Exon 12, c.1783_1790 del 8 mer N V <1% severe
119 M Affected case Exon 12, c.1804, C>T, CGA>TGA.Arg>X R V 1.5% moderate
150-1 M Affected case Exon 12, c.1834, C>T, CGC>TGC, Arg>Cys R 6.0% mild
10-1 M Affected case Exon 14, c.2314 C>T, CAA>TAA, Gln>X R <1% severe
104-1 M Affected case Exon 14, c.2605_2606, ins C N V <1% severe
113-1 M Affected case Exon 14, c.2609_2610, del CT R V <1% severe
85-1 M Affected case Exon 14, c.2939_2940, ins G N V <1% severe
124 M Affected case Exon 14, c.3294_3295, ins A N V 0.2% severe
111 M Affected case Exon 14, c.3629, del A R V <1% severe
17-1 F Carrier Exon 14, c.3629, del A R
3-1 M Affected case Exon 14, c.3629, del A R <1% severe
132 M Affected case Exon 14, c.4076 G>A, TGG>TAG, Trp>X R 0.3% severe
87-1 M Affected case Exon 14, c.4197 del C N 3.0% moderate
63-1 M Affected case Exon 14, c.4372, del A N 3.6% moderate
2-1 M Affected case Exon 14, c.4619, del T N <1% severe
11-1 F Affected case Exon14, c.4814, C>A, TCA>TAA, Ser>X R 2.0% moderate
57-2 M Affected case Exon 14, c.4856, del C R <1% severe
67-3 M Affected case Exon 14, c.4942 C>T, CAA>TAA, Gln>X 2.6% moderate
115-1 M Affected case Exon 14, c.5069_5073, del 5 mer R V <1% severe
74 M Affected case Exon14, c.5143, C>T, CGA>TGA, Arg>X N <1% severe
39-3 M Affected case Exon 15, c5343 T>A, TATA>TAA, Tyr>X N <1% severe
48-5 M Affected case Exon 15, c.5353, G>A, GAA>AAA, Glu>Lys N V 3.7% moderate
159-2 M Affected case Exon 16, c.5399, G>A, CGT>CAT, Arg>His R 4.5% moderate
97 M Affected case Exon 16, c.5465_5466, insA N 4.9% moderate
55-1 M Affected case Exon 16, c.5526, G>A, ATG>ATA, Met>Ile R 2.1% moderate
5-2 M Affected case Exon 16, c.5536, T>A, AAA>TAA, Lys>X R 1.6% moderate
123 M Affected case Exon 16, c.5576, A>G, GAT>GGT, Asp>Gly N indistinguishable 1.3% moderate
161-1 F Carrier Exon 17, c.5711, A>G, GAG>GGG, Glu>Gly N V
56-1 M Affected case Exon 17, c.5848, C>T, CGA>CAA, Gln>X N <1% severe
1-1 M Affected case Exon 18, c.5879, G>A, CGA>CAA, Arg>Gln R 7.4% mild
133 M Affected case Exon 18, c.5879, G>A, CGA>CAA, Arg>Gln R 5.5% mild
107-1 M Affected case Exon 18, c.5953, C>T, CGA>TGA, Arg>X R V 0.8% severe
138-2 M Affected case Exon 18, c.5953, C>T, CGA>TGA, Arg>X R <1% severe
73 M Affected case Exon 22, c.6403, C>T, CGA>TGA, Arg>X N <1% severe
14-2 M Affected case Exon 23, c.6506, G>A, CGT>CAT, Arg>His R 25% mild
20-1 M Affected case Exon 23, c.6506, G>A, CGT>CAT, Arg>His R 2.9% moderate
139-1 M Affected case Exon 23, c.6506, G>A, CGT>CAT, Arg>His R V 3.0% moderate
125 M Affected case Exon 23, c.6532, C>T, CGC>TGC, Arg>Cys R 6.5% mild
170-1 M Affected case Exon 23, c.6532 C>T, CGC>TGC, Arg>Cys R V 8.9% mild
174-1 M Affected case Exon 23, c.6532 C>T, CGC>TGC, Arg>Cys R V 8.4% mildBMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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95-1 M Affected case Exon 23, c.6545, G>A, CGC>CAC, Arg>His R V 2.5% moderate
38-3 M Affected case Exon 24, c. 6575 G>T, AGT>ATT, Ser>Ile R 7.2% mild
102-1 M Affected case Exon 24, c.6671, C>T, CCT>CTT, Pro>Leu R V 2.7% moderate
12-1 F Affected case Exon 24, c.6683 G>A, CGA> CAA, Arg>Gln R <1% severe
41-3 M Affected case Exon 25, c.6724, G>A, GTG>ATG, Val>Met; 
Exon 8, c.1172, G>A, CGC>CAC, Arg>His
R;R indistibuishable; V <1% severe
84-1 M Affected case Exon 25, c.6794_6795 del AG R indistinguishable <1% severe
93-1 M Affected case Intron 1 inversion R 12.0% mild
21-1 M Affected case Intron 22 inversion/Exon14 c.4531, G>A, 
GTT>ATT, Val>Ile
R;N V <1% severe
100 M Affected case Intron 22 inversion R <1% severe
103-1 F Carrier Intron 22 inversion R
105 M Affected case Intron 22 inversion R <1% severe
106-1 M Affected case Intron 22 inversion R <1% severe
112-1 M Affected case Intron 22 inversion R 1.2% moderate
116-1 M Affected case Intron 22 inversion R <1% severe
117 M Affected case Intron 22 inversion R 3.0% moderate
120-1 M Affected case Intron 22 inversion R 2.0% moderate
121 M Affected case Intron 22 inversion R 0.6% severe
126-1 M Affected case Intron 22 inversion R <1% severe
131-1 M Affected case Intron 22 inversion R <1% severe
13-4 M Affected case Intron 22 inversion R <1% severe
140 M Affected case Intron 22 inversion R 1.1% moderate
143-1 M Affected case Intron 22 inversion R 3.0% moderate
147 M Affected case Intron 22 inversion R 0.5% severe
149-2 M Affected case Intron 22 inversion R <1% severe
151 M Affected case Intron 22 inversion R 1.4% moderate
15-1 M Affected case Intron 22 inversion R <1% severe
152 M Affected case Intron 22 inversion R 2.1% moderate
153 M Affected case Intron 22 inversion R 1.8% moderate
154 M Affected case Intron 22 inversion R 0.5% severe
155 M Affected case Intron 22 inversion R 1.7% moderate
156 M Affected case Intron 22 inversion R 1.8% moderate
164 M Affected case Intron 22 inversion R <1% severe
167 M Affected case Intron 22 inversion R <1% severe
181 M Affected case Intron 22 inversion R 3.0% moderate
31-7 F Carrier Intron 22 inversion R
33-3 M Affected case Intron 22 inversion R <1% severe
34-1 M Affected case Intron 22 inversion R <1% severe
35-1 M Affected case Intron 22 inversion R 3.0% moderate
40-2 M Affected case Intron 22 inversion R <1% severe
47-1 M Affected case Intron 22 inversion R 3.2% moderate
58-3 M Affected case Intron 22 inversion R <1% severe
60-1 M Affected case Intron 22 inversion R 1.6% moderate
6-1 M Affected case Intron 22 inversion R <1% severe
51-1 M Affected case Intron 22 inversion R 2.7% moderate
62-1 M Affected case Intron 22 inversion R <1% severe
64-2 M Affected case Intron 22 inversion R <1% severe
68-1 M Affected case Intron 22 inversion R <1% severe
70-1 M Affected case Intron 22 inversion R <1% severe
75-2 M Affected case Intron 22 inversion R <1% severe
76-1 M Affected case Intron 22 inversion R <1% severe
77-1 M Affected case Intron 22 inversion R <1% severe
81 M Affected case Intron 22 inversion R <1% severe
86-2 M Affected case Intron 22 inversion R <1% severe
88-1 M Affected case Intron 22 inversion R <1% severe
89-1 M Affected case Intron 22 inversion R <1% severe
90 M Affected case Intron 22 inversion R 0.8% severe
91 M Affected case Intron 22 inversion R 1.1% moderate
9-1 M Affected case Intron 22 inversion R <1% severe
96-2 M Affected case Intron 22 inversion R 0.5% severe
99 M Affected case Intron 22 inversion R <1% severe
148 M Affected case Intron 22 inversion R <1% severe
Table 3: The detailed patient data. (Continued)BMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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tinguish the female carriers from the wild type. We
designed the multiplex PCR [12,15] so that we could dif-
ferentiate between them by examining different peak
heights with the use of different gene dosages(Fig 4). In
addition, the absence of peaks from exon 4 to exon 10
confirmed the deletion in the affected male. Multiplex
PCR is an in-house designed reaction, which compares the
dosage of several genes. This system may also be adapted
for diagnostic use in other genetic diseases involving dele-
tion and duplication mutations.
We had two heterozygous females from two unrelated
families. Hemophilia A is transmitted through hetero-
zygous females denoted as carriers, who are generally
asymptomatic. This is because random X inactivation
results in approximately equal proportions of somatic
cells, in which either the normal X or the mutated X chro-
mosome is active [23,30]. Because females have two X
chromosomes and only 5% of FVIII is enough for the
body to maintain hemostasis, it is very rare to have a
female HA patient with very low FVIII activity and severe
bleeding symptoms [31]. Even though the disease is
extremely rare in females, a few cases have been docu-
mented as a result of different pathophysiologic mecha-
nisms [32-34]. The skewed X-chromosome inactivation is
the most common possible mechanism for the phenome-
non [31,35-39].
The hemophilia A mutation screening is laborious and
expensive, even when employing DHPLC as a screening
method. In order to facilitate throughput and minimize
the cost of hemophilia A mutation screening, we evalu-
ated a new mutation scanning technique, high resolution
melting system(HRM). We performed high resolution
melting analysis on 43 samples, including carriers and
affected cases. All the carriers were easily to be distin-
guished (100%). Nevertheless, we were unable to identify
three out of 28 affected cases. The detection rate was 93%.
We had a reason to believe that it is easier for the heter-
oduplex to release double-stranded DNA dye, so that
HRM is more sensitive to carrier detection. DHPLC is not
ideal in detecting affected case until mixed together with
normal DNA. On the other hand, even though HRM was
able to distinguish the affected male from the wild type,
Comparison of the results of different HRM primers Figure 3
Comparison of the results of different HRM primers. a) and c) are HRM plots for exon 14-5 with first-designed primer. 
We are unable to see the grouping in the normalized, temperature-shifted plot. So we redesigned the primer pairs by LightCy-
cler Probe Design Software 2.0. The result is shown in b) and d). The carrier and the patient are easy to be distinguished in the 
latter.BMC Medical Genetics 2008, 9:53 http://www.biomedcentral.com/1471-2350/9/53
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the sensitivity did not reach 100% despite optimizing
condition. Therefore, mixing up the affected male DNA
with normal control would improve the detection rate for
both DHPLC and HRM. Besides, we proved that the anal-
ysis was greatly enhanced by good primer design that
avoided DNA-dimer formation. The sensitivity of the
analysis was not only influenced by the size of PCR prod-
ucts but also the primers and the PCR condition. We rec-
ommend the software, LightCycler Probe Design Software
2.0, as the tool for primer design.
As for clinical application, once the intron 1 and 22 inver-
sion has been ruled out, HRM becomes a good initial
screening method, especially for those families with obli-
gate carriers. Comparing with our familiar method,
DHPLC, HRM costs less ($0.6 versus $3.0 per sample per
amplicon, respectively), takes less time (3 hours versus 10
hours) and works more efficiently (96 or 384 wells at one
time). The analysis of HRM takes only fifteen minutes.
With this highly sensitive and specific tool, we will be able
to manage a large quantity of clinical samples and do
mutation screening.
Conclusion
In conclusion, we are capable of detecting 100% of muta-
tions in the F8 gene; also our study identified a number of
novel mutations in the largest cohort of Taiwanese
patients yet to be reported. Furthermore, we validate HRM
for hemophilia A mutation screening. Mutation detection
is best started with obligate carriers. We proposed a cost-
effective screening protocol with sequential combination
of different genetic diagnostic tools. HRM saves time and
money, and we have proven the use of such technique to
be effective for mutation screening.
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